Coherus Biosciences Inc’s recent filing unveils that its President & CEO Lanfear Dennis M unloaded Company’s shares for reported $0.45 million on Nov 22 ’23. In the deal valued at $2.02 per share,223,100 shares were sold. As a result of this transaction, Lanfear Dennis M now holds 731,693 shares worth roughly $0.76 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
UBS downgraded its Coherus Biosciences Inc [CHRS] rating to a Neutral from a a Buy in a research note published on August 16, 2024; the price target was decreased to $1.50 from $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. Maxim Group also remained covering CHRS and has decreased its forecast on November 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on July 24, 2023. It rated CHRS as “a Buy”.
Price Performance Review of CHRS
On Tuesday, Coherus Biosciences Inc [NASDAQ:CHRS] saw its stock fall -2.80% to $1.04. Over the last five days, the stock has gained 1.96%. Coherus Biosciences Inc shares have fallen nearly -68.77% since the year began. Nevertheless, the stocks have fallen -72.27% over the past one year. While a 52-week high of $3.98 was reached on 01/02/24, a 52-week low of $0.97 was recorded on 09/23/24. SMA at 50 days reached $1.2529, while 200 days put it at $1.9318.
Levels Of Support And Resistance For CHRS Stock
The 24-hour chart illustrates a support level at 1.0133, which if violated will result in even more drops to 0.9867. On the upside, there is a resistance level at 1.0833. A further resistance level may holdings at 1.1267. The Relative Strength Index (RSI) on the 14-day chart is 40.79, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0099, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.07%. Stochastics %K at 29.82% indicates the stock is a holding.
How much short interest is there in Coherus Biosciences Inc?
A steep rise in short interest was recorded in Coherus Biosciences Inc stocks on 2024-09-13, growing by 1.09 million shares to a total of 25.09 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 24.01 million shares. There was a rise of 4.33%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 01, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
